Myriad Discloses Unauthorized IT Access, Temporarily Halts Testing and Orders
MYGN has more than doubled off its 52-week low of $2.74.
Summary
Myriad Genetics disclosed unauthorized access to its IT network on November 2, 2026, which forced it to temporarily suspend testing operations and order intake. The disclosure follows the 8-K filed earlier today and lands one day after the company reported a $43.9 million third-quarter loss on $202.7 million of revenue. For a lab operator, a testing halt is the revenue engine stalling — every day of suspended orders and sample processing is deferred or lost volume, and the company has not yet quantified the duration or financial impact. The breach also arrives while Myriad is mid-divestiture, having agreed on October 20 to sell its prenatal testing franchise to Labcorp for $210 million, so any operational disruption or remediation cost touches a business already being reshaped.
At the time of this announcement, MYGN was trading at $6.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $600.2M. The 52-week trading range was $2.74 to $8.09. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.